Research on the inhibiting effect of tanshinone IIA on colon cancer cell growth via COX-2-Wnt/β-catenin signaling pathway.
To investigate the effects of tanshinone IIA (TSIIA) on the colon cancer cell growth and to explore the mechanism of TSIIA in regulating the colon cancer cell growth via cyclooxygenase (COX)-2-Wnt/β-catenin signaling pathway. Colon cancer cell line HC8693 was exposed to different concentrations of TSIIA. After 24-hr exposure, MTT assay was used to detect the lethal concentration of TSIIA on HC8693 cells. The expression levels of COX-2 and β-catenin were detected by semi-quantitative PCR (sq-PCR). The protein expression levels of COX-2 and β-catenin were detected by Western blot, and the expression of vascular endothelial growth factor (VEGF) was detected by enzyme-linked immunosorbent assay (ELISA). Celecoxib, a COX-2 selective inhibitor, was used to inhibit the COX-2 of HC8693 cells, and the inhibiting effect of TSIIA on HC8693 cell growth was assessed. MTT assay showed that TSIIA concentration of 20μM inhibited significantly the HC8693 cell growth (p<0.01). With reverse transcription after RNA extraction and (sq-PCR) detection the expression levels of COX-2 and β-catenin were significantly decreased (p<0.01). Western blot showed that the protein expression levels of COX-2 and β-catenin were significantly decreased (p<0.01). ELISA showed that the expression of VEGF was also significantly decreased (p<0.01); after celecoxib (10μM) was added, 20μM TSIIA had no inhibiting effect on the growth of HC8693 cells (p>0.05). Western blot showed no significant differences in the protein expression levels of COX-2 and β-catenin compared with those in the control group (not exposed to TSIIA). TSIIA can inhibit the expression of COX-2 and activate the Wnt/β-catenin signaling pathway, thus downregulating the level of VEGF, and resulting in growth inhibition of colon cancer cells.